News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Celgene Reports Record Non-GAAP Fourth Quarter and Full Year 2010 Operating and Financial Results
January 27, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG): This operating momentum, combined with our continued investment in R&D, positions us well for sustained growth in both the near and long term.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
FDA
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
September 2, 2026
·
2 min read
·
Jef Akst
Cancer
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
September 1, 2026
·
2 min read
·
Annalee Armstrong
Layoffs
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
September 1, 2026
·
1 min read
·
Tristan Manalac
Legal
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
August 31, 2026
·
2 min read
·
Annalee Armstrong